8.7 C
London
Friday, November 8, 2024
HomeTagsTherapeutics

Tag: Therapeutics

spot_imgspot_img

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery...

EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies

HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents...

HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate...

ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024 - (ACN Newswire) - HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development...

Gilboa Therapeutics Presents Pre-clinical Data at AACR Supporting SolidT Engineered T-Cell Platform Targeting Solid Tumors

Gilboa will present in vitro and in vivo data at the AACR Annual Meeting demonstrating non-clinical proof of concept for SolidT cells co-administered with...

Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer

 Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound,...

Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

MELBOURNE, Jan 16, 2024 - (ACN Newswire) - Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy...

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img